Open AccessDose-Response Following Single Administrations of a New Cardiac Performance Enhancer RO 13–6438 in Normal Volunteers
Author(s) -
Belz Gg,
Stern Hc,
R. Butzer
Publication year - 1985
Publication title -
journal of cardiovascular pharmacology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.762
H-Index - 100
eISSN - 1533-4023
pISSN - 0160-2446
DOI - 10.1097/00005344-198501000-00014
Subject(s) - medicine , crossover study , impedance cardiography , heart rate , placebo , inotrope , heart failure , cardiac output , vasodilation , bioavailability , cardiology , cardiac function curve , pharmacokinetics , blood pressure , anesthesia , pharmacology , stroke volume , alternative medicine , pathology
We assessed the changes in cardiovascular function in humans caused by RO 13-6438, a new drug that enhances cardiac performance, by means of noninvasive methods which included measurement of systolic time intervals and electrical impedance cardiography. Twelve healthy male volunteers received RO 13-6438 doses of 10 and 20 mg intravenously and 20, 40, and 60 mg orally according to a double blind, randomized, crossover, placebo-controlled design. A dose-dependent distinct enhancement in cardiac performance was seen. This was attributed to positive inotropism (shortening of heart rate-corrected electromechanical systole) and to a vasodilating action (decline of diastolic blood pressure and total peripheral resistance). In addition, the drug increased heart rate slightly. The cardiac effects were detectable for 6 h. To reach the average equivalent inotropic response over 6 h, the oral dose was approximately 1.8-fold of the i.v.; this indicated a high bioavailability of RO 13-6438. Transient color vision disturbances were reported mainly following the intravenous administration. The properties of RO 13-6438 suggests that it may be useful for treatment of heart failure.